News

NewAmsterdam Pharma's Upcoming Medical Engagements and Updates

NewAmsterdam Pharma's Upcoming Medical Engagements and Updates

NewAmsterdam Pharma's Upcoming Medical Engagements

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a prominent player in the late-stage biopharmaceutical sector, has exciting developments on the horizon. With a focus on advancing patient care for those grappling with cardiovascular disease, the company is gearing up for its presentations at significant medical meetings and investor conferences.

AHA Scientific Sessions 2025 Presentation Details

One of the key highlights will be NewAmsterdam's presentation of safety and efficacy data from its pivotal Phase 3 trials: BROOKLYN, BROADWAY, and TANDEM. These trials are crucial in exploring the effectiveness of oral, non-statin medicines for individuals with heightened low-density lipoprotein cholesterol.

AHA Presentation Titles

The first noteworthy presentation is titled "Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles." This oral presentation is scheduled for November 9, 2025, at 10:15 am CT, featuring insights from lead presenter John Kastelein.

Following this, there will be a digital poster presentation on "Obicetrapib in Combination with Ezetimibe on Top of Atorvastatin Regresses Atherosclerotic Plaque Lesions in APOE*3-Leiden CETP Mice." This innovative presentation is set for November 10, 2025, at 10:59 am CT, showcasing the work of Jose Inia.

Upcoming Investor Conferences

NewAmsterdam Pharma also has a robust schedule for investor interactions, starting with the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, at 10:30 am ET in Boston. Key representatives will include their Chief Executive Officer Michael Davidson, M.D., and Chief Financial Officer Ian Somaiya.

Following that, on November 12, 2025, at 8:00 am ET, they will participate in the Stifel Healthcare Conference, providing another platform for investors to engage with company leadership.

Lastly, on November 19, 2025, at 5:00 pm GMT, they will feature at the Jefferies London Healthcare Conference, where Ian Somaiya will be joined by John Kastelein, M.D., Ph.D., the Founder and Chief Scientific Officer. These platforms will not only provide valuable insights into the company's ongoing research but also allow for direct engagement with the leadership team.

Accessing Live Webcasts

Live webcasts of these investor discussions will be accessible via the investor relations section of NewAmsterdam Pharma's website. These discussions will be archived for future viewing, enabling stakeholders and interested parties to gain insights into the company's strategies and research outcomes.

About NewAmsterdam

NewAmsterdam Pharma is dedicated to enhancing patient care in metabolic diseases where existing therapies fall short. Their investigation of obicetrapib aims to offer a well-tolerated and effective LDL-lowering treatment for patients at risk of cardiovascular complications. In their ongoing Phase 3 trials, they explore this treatment's efficacy in combination with existing medications for holistic cardiovascular care.

Company Contact Information

Contact Matthew Philippe for corporate inquiries at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com.

Media and Investor Contacts

For media inquiries, contact Real Chemistry on behalf of NewAmsterdam, Christian Edgington at 1-513-310-6410 or via email at cedgington@realchemistry.com.

For investor communications, reach out to Austin Murtagh from Precision AQ at 1-212-698-8696 or at austin.murtagh@precisionaq.com.

Frequently Asked Questions

What is NewAmsterdam Pharma known for?

NewAmsterdam Pharma specializes in developing innovative therapies aimed at addressing cardiovascular disease, focusing on LDL-lowering treatments.

When are NewAmsterdam's major upcoming presentations?

The key presentations at the AHA Scientific Sessions will occur on November 9 and 10, 2025.

How can I access the investor conferences?

Live and archived webcasts of the investor discussions will be available on NewAmsterdam's investor relations website.

Who will be presenting at the conferences?

Key executives including CEO Michael Davidson and CFO Ian Somaiya will represent the company at the various conferences.

What are the main trials being discussed?

The presentations will cover findings from the BROOKLYN, BROADWAY, and TANDEM trials focusing on obicetrapib's efficacy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 63

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 89

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 51

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 139

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 65

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
Bella Rio's Proposed Preferred B Share Giveaway Plan

Updated Category News Views 24

A founder handing over two million of his own common shares is the sort of detail that makes investors stop stirring their coffee. Bella Rio Consulting, the company behind ROCK'N Vodka and Bella Rio Bourbon, says co-founder and Vice President Andy Roiniotis proposes to contribute 2,000,000 personally held Common shares for reclassification into Preferred Series B shares....

Continue Reading
2027 Auto Brand Awards Put Long-Term Buyer Value First Again

Updated Category News Views 81

Car shoppers staring down high prices and financing costs do not need another shiny badge; they need some help separating durable value from showroom wallpaper. That is why the 2027 U.S. News vehicle brand awards, announced Nov. 19, 2026, are worth a look. They are not a sales forecast, not a profit forecast, and certainly not a reason to blindly crown a corporate winner....

Continue Reading
Trip.com Sets December 1 Date for Third-Quarter Results

Updated Category News Views 108

December’s first after-hours session will put Trip.com Group back under the market’s microscope, whether anybody is ready or not. The company says it will report results for the three months ended September 30, 2026 after the U.S. market closes on Tuesday, December 1. That is the whole hard-news payload for now: a reporting date, a call time, and no numbers to get...

Continue Reading

Top 5 Most Recently Viewed Articles

Greenwave Technology's Bold $4 Million Rare Earth Metals Strategy

Updated Category News Views 181

Greenwave Technology Solutions Takes Bold Steps Greenwave Technology Solutions, Inc. (NASDAQ: GWAV) recently announced a significant initiative to enhance its capabilities in rare earth metals recovery. This strategy entails raising $4 million through a securities purchase agreement with institutional and accredited investors. With a current market capitalization of...

Continue Reading
Exploring NewAmsterdam Pharma's Breakthrough Alzheimer’s Findings

Updated Category News Views 164

NewAmsterdam Pharma Unveils Exciting Alzheimer’s Data NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) has made strides in the study of Alzheimer’s disease. During a recent conference, the company presented compelling data from its BROADWAY trial, focusing on significant reductions in key Alzheimer’s biomarkers. This innovative research highlights obicetrapib's...

Continue Reading
Persistent Systems Reports Impressive Q3 Growth and Innovation

Updated Category News Views 202

Persistent Systems Achieves Strong Financial Performance Declares interim dividend of ?20 per share Persistent Systems (BSE: 533179) (NSE: PERSISTENT) has announced impressive financial results for the quarter ending December 31, showcasing a total revenue of $360.2 million. This success marks a 4.3% increase quarter-over-quarter and an outstanding 19.9% year-over-year...

Continue Reading
Nasdaq Announces Market Closure in Tribute to President Carter

Updated Category News Views 122

Nasdaq to Honor President Carter with Market Closure In a significant gesture of respect, Nasdaq (NASDAQ:NDAQ), a prominent market operator, will close all U.S. equities and options markets on January 9, 2025. This closure comes in memory of the former President Jimmy Carter, honoring his profound impact on American society. The announcement coincides with the nation’s...

Continue Reading
How a $100 Investment in Tenet Healthcare Could Grow Today

Updated Category News Views 187

The Remarkable Journey of Tenet Healthcare Tenet Healthcare (NYSE: THC) has shown impressive growth and resilience over the past 15 years. On average, the company has outstripped market returns by 5.36% annually, delivering an average annual return of 17.55%. With a current market capitalization of $17.35 billion, Tenet has proven to be a strong player in the healthcare...

Continue Reading